Skip to main content

Table 1 Subject randomization

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Group Name Sample size Compound Dosage
A 0 Placebo n = 15 Placebo N/A (CMC capsule b.i.d)
A 1 Dose 1 n = 15 UP446 250 mg/day (125 mg b.i.d.)
A 2 Dose 2 n = 15 UP446 500 mg/day (250 mg b.i.d.)
A 3 Dose 3 n = 15 Celecoxib 200 mg/day (100 mg b.i.d.)
  1. Acetaminophen was provided as rescue medication. Subjects were permitted to take up to 1000 mg t.i.d.